IVERIC Bio: Undeniable Promising News Today

IVERIC Bio ~ September 6, 2022
IVERIC bio (ISEE) announced positive results from GATHER2 second Phase 3 clinical trial of Zimura® (avacincaptad pegol) - a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA).

GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.